Therapy News and Research

RSS

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

19 Jul 2010

Erie County Medical Center to implement Allscripts EHR

Allscripts announced today that Erie County Medical Center Corporation, a 550-bed academic medical center in Buffalo, has selected the Allscripts Electronic Health Record (EHR) for 100 of its physicians to enhance the quality of patient care, improve physician and patient communications, and better manage the cost of care delivery in 24 outpatient clinics.

19 Jul 2010

EndoStim raises $6M in Series B equity financing round

EndoStim, Inc., a medical device company developing minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, today announced it has raised $6 million in Series B equity financing. Santé Ventures, a life science venture capital firm, led the round and was joined by the Prolog Ventures, Vectis Healthcare & Life Sciences Fund II and returning angel investors.

19 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

From Novo Nordisk 19 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.

19 Jul 2010

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Take a skin cell from a patient with Type 1 diabetes. Strip out everything that made it a skin cell, then reprogram it to grow into a colony of pancreatic beta cells. Implant these into your patient and voilà! She's producing her own insulin like a pro.

19 Jul 2010

Effective AIDS treatment but poor accessibility: Report from International AIDS conference 2010

At the 18th AIDS conference 2010 in Vienna, Julio Montaner — the President of the International AIDS Society and Chairman of the AIDS 2010 conference said this Sunday that the G-8 countries were not doing enough to ensure treatment of all people infected with HIV and AIDS. He said, “This is a very serious deficit… Let's rejoice in the fact that today we have treatments that work ... what we need is the political will to go the extra mile to deliver universal access.”

18 Jul 2010

Relationship between music, neurosciences to be discussed in a conference at Edinburgh

The Mariani Foundation for Paediatric Neurology announces "The Neurosciences and Music - IV: Learning and Memory", to be held in Edinburgh (Scotland, UK) from 9th to 12th June 2011. The conference is conceived as a continuation of the previous meetings on the relation between music and the neurosciences in which our foundation participated: "The Biological Foundations of Music" (New York, 2000), "The Neurosciences and Music, Mutual Interactions and Implications of Developmental Functions" (Venice, 2002), "The Neurosciences and Music - II, From Perception to Performance" (Leipzig, 2005) and "The Neurosciences and Music - III, Disorders and Plasticity".

17 Jul 2010

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

DOJ-HHS Medicare Fraud Strike Force charges 94 people for $251 million in false claims

Ninety-four people have been charged for their alleged participation in schemes to collectively submit more than $251 million in false claims to the Medicare program in the continuing operation of the Medicare Fraud Strike Force in Miami; Baton Rouge, La.; Brooklyn, N.Y.; Detroit and Houston, announced Attorney General Eric Holder, Department of Health and Human Services (HHS) Secretary Kathleen Sebelius, FBI Director Robert Mueller and Daniel R. Levinson, Inspector General of HHS.

17 Jul 2010

Proton therapy treatment for anal canal cancer performed for first time in US

The INTEGRIS Cancer Institute of Oklahoma and the ProCure Proton Therapy Center announce a breakthrough treatment approach for anal canal cancer. For the first time in the United States proton therapy is now being used to treat this type of cancer.

17 Jul 2010

IAS announces winners of four scientific awards to be presented at AIDS 2010

The International AIDS Society (IAS) announced today the ten winners of four prestigious scientific awards, to be presented at plenary sessions during the XVIII International AIDS Conference (AIDS 2010). Presented by the IAS and partners, these awards recognize scientists involved in innovative HIV and AIDS research throughout the world. "The quality of work represented by the 2010 awardees is remarkable," said IAS President Julio Montaner. "The IAS hopes to draw the world's attention to these individuals and to their significant scientific accomplishments, as well as to the continued need for innovation in all of the major areas of HIV and AIDS research, represented by the six conference programme tracks."

17 Jul 2010

Study examines HIV-positive patients' death risk at CD4 counts above 350

"Having HIV appears to be associated with a greater risk of death, even when the immune system is relatively robust and patients have not started treatment," according to a study published Friday in the Lancet, MedPage Today reports (Smith, 7/15).

17 Jul 2010

Epizyme publishes two new review papers on epigenetics

Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.

17 Jul 2010

Amgen granted FDA priority review designation for denosumab BLA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

17 Jul 2010

94 indicted in five-state crackdown on Medicare fraud

Law enforcement officers fanned out across five states Friday in what federal officials called the largest Medicare fraud bust ever conducted. Nearly 100 people were indicted in frauds that totaled $251 million.

17 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

Philadelphia to host 52nd annual meeting of American Association of Physicists in Medicine

Next week the city of Philadelphia will host the 52nd annual meeting of the American Association of Physicists in Medicine (AAPM), the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology.

16 Jul 2010

Therapy News and Research

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Erie County Medical Center to implement Allscripts EHR

EndoStim raises $6M in Series B equity financing round

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Effective AIDS treatment but poor accessibility: Report from International AIDS conference 2010

Relationship between music, neurosciences to be discussed in a conference at Edinburgh

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

DOJ-HHS Medicare Fraud Strike Force charges 94 people for $251 million in false claims

Proton therapy treatment for anal canal cancer performed for first time in US

IAS announces winners of four scientific awards to be presented at AIDS 2010

Study examines HIV-positive patients' death risk at CD4 counts above 350

Epizyme publishes two new review papers on epigenetics

Amgen granted FDA priority review designation for denosumab BLA

94 indicted in five-state crackdown on Medicare fraud

An overview of AAPM annual meeting

Philadelphia to host 52nd annual meeting of American Association of Physicists in Medicine

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News